AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16237467
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for gastric cancer
Trial: 11888754
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg/24 h P.O. + 2x0.5 mg digoxin IV on the operating day + digoxin 0.25 mg P.O. + metoprolol 100 mg P.O. on the first postoperative day until discharge
Trial: 11888754
Drug: Amiodarone 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 1200 mg IV/24 h (300 mg bolus dose/1 h post-operation, then 450 mg/24 h IV and 600 mg/day P.O. until discharge)
Trial: 8597006
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) at 2.5 mg/kg/d
Trial: 8597006
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) at 5.0 mg/kg/d
Trial: 29921405
Drug: Automatic reposition
RxNorm normalized name: AMMONIA,AROMATIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic reposition treatment
Trial: 29921405
Drug: Manual reposition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual reposition treatment
Trial: 26838074
Drug: XueBiJing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XueBiJing injection (intravenous infusion)
Trial: 17172550
Drug: Intensive traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive traditional therapy
Trial: 15678729
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate infusion (5 mg kg(‐1) bolus followed by 500 mg h(‐1) infusion for 24 h)
Trial: 15678729
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline infusion in the same volumes for 24 h)
Trial: 420135
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (155 cal and 20 g of protein per day)
Trial: 21998287
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for early syphilis
Trial: 26108088
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (FPNS) 200 mcg once daily
Trial: 23648948
Drug: BSS+ (Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSS+ (Behavioral Support Sessions plus bupropion therapy)
Trial: 19402296
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D injection (600,000 IU)
Trial: 17367443
Drug: Topical verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical verapamil hydrochloride 15% gel applied twice daily for 3 months, followed by open label for 6 months.
Trial: 9039201
Drug: Butenafine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butenafine 1% cream applied once daily for 2 weeks
Trial: 9039201
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied once daily for 2 weeks
Trial: 27306272
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioral Therapy for Insomnia (GT)
Trial: 27306272
Drug: Internet Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet Cognitive Behavioral Therapy for Insomnia (IT)
Trial: 28555208
Drug: One-piece implants
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-piece implants (OPI)
Trial: 28555208
Drug: Two-piece implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-piece implants (TPI)
Trial: 1579326
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (missing pills on days 1-4)
Trial: 1579326
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (missing pills on days 3-6)
Trial: 1579326
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (missing pills on days 6-9)
Trial: 31309643
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day sesamin supplement
Trial: 27461767
Drug: TIVA0 (manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA0 (manual infusion guided by clinical signs)
Trial: 27461767
Drug: TIVABIS (BIS-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVABIS (BIS-guided infusion)
Trial: 27461767
Drug: TCI KBIS
RxNorm normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI KBIS (BIS-guided target controlled infusion with Kataria model)
Trial: 27461767
Drug: TCI SBIS
RxNorm normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI SBIS (BIS-guided target controlled infusion with Schnider model)
Trial: 24528939
Drug: HPLC diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPLC diet (very low carbohydrate, 22 g/d)
Trial: 24528939
Drug: HPMC diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC diet (moderate carbohydrate, 182 g/d)
Trial: 16268973
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg/day and then 600 mg/day
Trial: 10402403
Drug: rec-FSH (Gonal-F,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rec-FSH (Gonal-F, Serono) at a fixed dose of 150 IU/day for 3 days
Trial: 10402403
Drug: rec-FSH (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rec-FSH (150 IU/daily) continued until follicles were 10 mm in diameter, aspiration performed 72 h later
Trial: 7554064
Drug: 300 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g/day cooked Brussels sprouts
Trial: 547122
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of scopolamine and physostigmine
Trial: 28093928
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical stimulation therapy
Trial: 26346300
Drug: roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 300 mg daily and doxycycline 100 mg daily
Trial: 26346300
Drug: roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 300 mg daily
Trial: 16435344
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (ESWT) with approximately 3,800 total shock waves, total energy delivery of 1,300 mJ/mm(2) in a single session
Trial: 14755147
Drug: Procaine 2
RxNorm normalized name: procaine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine 2 g/24 h by continuous intravenous infusion
Trial: 14755147
Drug: Pentazocine 30
RxNorm normalized name: pentazocine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 30 mg every 6 h as a bolus intravenous injection
Trial: 29608768
Drug: Crushed intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed intranasal oxycodone ARIR
Trial: 15198118
Drug: Aromatherapy massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy massage (weekly for four weeks)
Trial: 11285662
Drug: Mass treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass treatment of all children
Trial: 11285662
Drug: Targeted treatment
RxNorm normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatment of clinically active children and their household members
Trial: 22035502
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in the patient's home
Trial: 22035502
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in GP surgeries
Trial: 18667247
Drug: Intensive Treatment
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Treatment (Atorvastatin 80 mg immediately after admission)
Trial: 18667247
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (Atorvastatin 20 mg from the day of discharge)
Trial: 16556892
Drug: HDC/IL-2 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDC/IL-2 treatment (10 cycles of IL-2 at 16,400 U/kg and HDC at 0.5 mg, administered subcutaneously twice daily)
Trial: 12875348
Drug: A-Cnotren/Pharmaten, Athens,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-Cnotren/Pharmaten, Athens, Greece (test preparation)
Trial: 8678384
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate lozenges (13.3 mg of zinc from zinc gluconate, one lozenge every 2 hours while awake)
Trial: 8678384
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (5% calcium lactate pentahydrate, one lozenge every 2 hours while awake)
Trial: 1840138
Drug: Paroxetine co-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine co-treatment for 16 days after a 7-day placebo treatment
Trial: 1840138
Drug: Paroxetine co-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine co-treatment
Trial: 6121568
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate 6 mg
Trial: 6121568
Drug: Methadone 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 6 mg
Trial: 6121568
Drug: Pethidine 60
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 60 mg
Trial: 17403074
Drug: PEG laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG laxative (17 g daily)
Trial: 17403074
Drug: PEG treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG treatment weeks
Trial: 17403074
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment weeks
Trial: 3757441
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium diet (1800 mg of calcium/day)
Trial: 3757441
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium diet (200 mg of calcium/day)
Trial: 23710881
Drug: Usual practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual practice of pharmacological emesis prevention (ondansetron 8 mg)
Trial: 20470796
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) regimen
Trial: 20470796
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) regimen
Trial: 18241082
Drug: Adaptive design
RxNorm normalized name: Designer Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive design for dose-response trials
Trial: 10770216
Drug: rhIGF‐I (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (60 microg/kg, sc, twice daily)
Trial: 8867568
Drug: Trandolapril (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (2-4 mg once-daily)
Trial: 1732769
Drug: High-osmolality contrast
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-osmolality contrast agent (Hypaque 76)
Trial: 1732769
Drug: Low-osmolality contrast
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-osmolality contrast agent (Omnipaque 350)
Trial: 26940805
Drug: ABT-126 10
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 10 mg
Trial: 26940805
Drug: ABT-126 25
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 25 mg (nonsmokers)
Trial: 17972024
Drug: EAP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAP regimen (doxorubicin 40 mg/m², etoposide 360 mg/m², cisplatin 80 mg/m² every 28 days)
Trial: 17972024
Drug: HD 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HD 5-FU (5-FU 2.6 g/m² 24 h infusion, biweekly)
Trial: 16898538
Drug: Selective alpha1-blocker
RxNorm normalized name: NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective alpha1-blocker (doxazosin)
Trial: 16898538
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy and rehabilitation
Trial: 14653830
Drug: Metronidazole 250
RxNorm normalized name: metronidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 250 mg t.d.s. for 10 days (Group A)
Trial: 14653830
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.d. for 10 days (Group B)
Trial: 10794751
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of intravenous ibandronate
Trial: 8799771
Drug: Environmental noises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental noises (e.g., baby's crying)
Trial: 1634646
Drug: Nisoldipine 30
RxNorm normalized name: nisoldipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 30 mg
Trial: 31673354
Drug: Alcohol-based hand
RxNorm normalized name: ALCOHOL 300 mL in 500 mL EXTRACORPOREAL GEL [JINHUI Alcohol-Based Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-based hand rub (ABHR) gel
Trial: 24277644
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered at 2 hours post-dose
Trial: 24277644
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered at 6 hours post-dose
Trial: 24277644
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered at 2 or 6 hours post-dose
Trial: 18815591
Drug: Ritonavir 20
RxNorm normalized name: ritonavir 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 20 mg
Trial: 18575010
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.5 mg/ml) applied intra- and postoperatively for 5 minutes
Trial: 17212078
Drug: Conventional cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cavity preparation
Trial: 10102460
Drug: Melagatran (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melagatran (low dose)
Trial: 10102460
Drug: Melagatran (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melagatran (medium dose)
Trial: 10102460
Drug: Melagatran (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melagatran (high dose)
Trial: 2348224
Drug: liposome‐encapsulated doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposome‐encapsulated doxorubicin (LED) at 30 mg/m2
Trial: 2348224
Drug: liposome‐encapsulated doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposome‐encapsulated doxorubicin (LED) at 45 mg/m2
Trial: 2348224
Drug: liposome‐encapsulated doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposome‐encapsulated doxorubicin (LED) at 60 mg/m2
Trial: 2348224
Drug: liposome‐encapsulated doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposome‐encapsulated doxorubicin (LED) at 90 mg/m2
Trial: 375768
Drug: Dantrolene (100-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dantrolene (100-150 mg)
Trial: 31250168
Drug: Intrarectal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal instillation of 2% lidocaine gel (group A)
Trial: 28510574
Drug: High initial
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High initial dosage (10 vials) of Indian polyvalent antivenom
Trial: 28510574
Drug: Low initial
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low initial dosage (2 vials) of Indian polyvalent antivenom
Trial: 23442273
Drug: Daily Nonlinear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Nonlinear Periodized (DNLP) training
Trial: 21168464
Drug: RIS oral
RxNorm normalized name: Feoris Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIS oral solution (mean dose, 3.7 mg)
Trial: 21168464
Drug: RIS standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIS standard tablets (mean dose, 3.7 mg)
Trial: 21168464
Drug: RIS oral
RxNorm normalized name: Feoris Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIS oral solution
Trial: 21168464
Drug: RIS standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIS standard tablets
Trial: 21168464
Drug: Both RIS
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both RIS oral solution and RIS standard tablets
Trial: 7618022
Drug: Zolpidem 7.5
RxNorm normalized name: zolpidem 7.5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 7.5 mg
Trial: 7618022
Drug: Zolpidem 7.5
RxNorm normalized name: zolpidem 7.5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 7.5 mg and 10 mg
Trial: 30301734
Drug: 17β-estradiol transdermal
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17β-estradiol transdermal patch continuously with cyclic oral micronised progesterone (PATCH)
Trial: 30476179
Drug: Combined ethinyl
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined ethinyl estradiol and desogestrel pill (PILL)
Trial: 10978851
Drug: Oral dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dietary supplements (ODS) pre- and postoperatively
Trial: 10978851
Drug: Oral dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dietary supplements (ODS) preoperatively only
Trial: 10978851
Drug: Oral dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dietary supplements (ODS) postoperatively only
Trial: 10978851
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral dietary supplements (Control group)
Trial: 1681563
Drug: Abecarnil 3-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abecarnil 3-9 mg/day
Trial: 1681563
Drug: Abecarnil 15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abecarnil 15-30 mg/day and 7.5-15 mg/day
Trial: 6130080
Drug: buspirone, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone, 20 mg/day
Trial: 6130080
Drug: diazepam, 20
RxNorm normalized name: DiazePAM, 20 mg rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam, 20 mg/day
Trial: 6130080
Drug: clorazepate, 23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clorazepate, 23 mg/day
Trial: 26271173
Drug: 13-valent polysaccharide
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent polysaccharide conjugate vaccine (PCV13)
Trial: 18947396
Drug: Lipoplus 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoplus 20% (50% MCT, 40% LCT, 10% omega‐3) administered at a dose of 0.12 g/kg/h for 12 hours
Trial: 18947396
Drug: Intralipid Fresenius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid Fresenius Kabi (100% LCT) administered at a dose of 0.12 g/kg/h for 12 hours
Trial: 15833501
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) 300 mg